AN2 Therapeutics (ANTX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
22 Apr, 2026Voting matters and shareholder proposals
Election of three Class I directors to serve until the 2029 annual meeting or until successors are appointed.
Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Proxy holders authorized to vote on other business properly brought before the meeting or any adjournments.
Board of directors and corporate governance
Board recommends voting "FOR" all director nominees and the auditor ratification proposal.
Nominees for Class I directors are Kabeer Aziz, Gilbert Lynn Marks, M.D., and Rob Readnour, Ph.D.
Audit committee and external auditor matters
Proposal to ratify PricewaterhouseCoopers LLP as the external auditor for the upcoming fiscal year.
Partial view of Summaries dataset, powered by Quartr API
Latest events from AN2 Therapeutics
- Boron-based therapies advance in hematology, infectious disease, and oncology with pivotal trials ahead.ANTX
Investor presentation23 Apr 2026 - Director elections, auditor ratification, and executive compensation are key meeting topics.ANTX
Proxy filing22 Apr 2026 - Biopharma seeks up to $300M via flexible offerings to fund R&D, with notable dilution risk.ANTX
Registration filing9 Apr 2026 - Reduced net loss, advanced clinical pipeline, and secured funding to extend runway into 2029.ANTX
Q4 202517 Mar 2026 - Epetraborole enters Phase 2 for PV, targeting oral hematocrit control and rapid clinical progress.ANTX
Leerink Global Healthcare Conference 202610 Mar 2026 - Epetraborole enters Phase 2 for PV, aiming for early, durable hematocrit control in 2026.ANTX
Status update4 Mar 2026 - Phase III NTM lung data and new infectious disease trials mark major 2024 milestones.ANTX
TD Cowen 45th Annual Healthcare Conference3 Feb 2026 - Phase III data for epetraborole in severe NTM lung disease expected Q2, with strong pipeline and cash runway.ANTX
Leerink’s Global Healthcare Conference 202526 Dec 2025 - Positive clinical signals and a strong pipeline position the company for key regulatory milestones.ANTX
Oppenheimer 35th Annual Healthcare Life Sciences Conference 202524 Dec 2025